Alectinib-Reference-Cited by-同舟云学术

Alectinib

Published:2018 Issue: Volume: Page:247-256
ISSN:0080-0015
Container-title:Recent Results in Cancer Research
language:
Short-container-title:

Author:

Herden M.,Waller Cornelius F.

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-319-91442-8_17

Reference32 articles.

1. Awad MM, Shaw AT (2014) ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 12:429–439

2. Costa DB et al (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881–1888

3. Dacic S et al (2016) ALK fish patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma. Oncotarget. https://doi.org/10.18632/oncotarget.12705

4. Gadgeel SM et al (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119–1128

5. Gainor JF, Yoda S et al (2016) Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6(10):1118–1133

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alectinib Induced SJS/TEN: A Case Report and a Review;TURK ONCOL DERG;2024

2. Review of indole, A versatile pharmacophoric moiety;Current Trends in Pharmacy and Pharmaceutical Chemistry;2024-05-15

3. A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol;2024-04-16

4. Knockdown of the VEGFB/VEGFR1 signaling suppresses pubertal mammary gland development of mice via the inhibition of PI3K/Akt pathway;International Journal of Biological Macromolecules;2024-04

5. Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer;International Journal of Molecular Sciences;2024-01-09